Global opportunities…. Datopotamab deruxtecan is an ADC targeting Trophoblast cell surface antigen 2 which received an accelerated approval from FDA and PMDA for patients with metastatic HER2-positive( a protein overexposed in solid tumours)breast cancer who have received two or more prior anti-HER2-based regimens now they are aiming at first line cancer patients combining the ADC with an immunotherapy drug. If approved this is a much larger market, point is the TH1902 if and when approved for late stage cancer/cancers could be just the beginning of various potentially therapeutic programs including earlier lines of cancers due to better affinity to the receptor or/and a combo therapy which is targeting much larger targeted cancer patients who will be healthy enough to take the drug for much longer than late stage cancer patients.
“These early findings from TROPION-Lung02 are promising and represent the first lung cancer trial to report results combining a TROP2 directed antibody drug conjugate with an immune checkpoint inhibitor with or without platinum chemotherapy in patients with advanced or metastatic non-small cell lung cancer,” said Gilles Gallant, BPharm, PhD, FOPQ, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo. “These data support the initiation of the TROPION-Lung08 phase 3 trial to further evaluate datopotamab deruxtecan in combination with pembrolizumab as a first-line combination treatment in patients with advanced non-small cell lung cancer without actionable genomic alterations.”
https://www.businesswire.com/news/home/20220808005728/en/Datopotamab-Deruxtecan-Based-Combinations-Show-Promising-Clinical-Activity-in-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer
I don’t have access to the report but THTX was mentioned here as contender in the PDC field as a novel therapy for cancer worldwide. There is global patent for their PDC technology in place which is inherited after the purchase of Katana but there will be small yet some milestone fees so Thereatetechnologies also applied for the below which was published in June 2021 awaiting approval.
WO2021108929A1 - Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer - Google Patents
Peptide-drug Conjugates (PDCs) Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic